The results of a study on mice taking NR (Niagen) which looked at effects on the heart were recently published in the Journal of the American College of Cardiology:
Prof. Ajay Shah at Kings College, a lead researcher of the study, said: “NR supplementation is a new and exciting intervention that merits testing in the human treatment of heart failure and other cardiac conditions,…These study findings showing the potential of NR to activate UPRmt are extremely encouraging and merit further research into the potential for NR to impact human cardiac health.”
“Additionally, NR helped improve mitochondrial function and maintained the heart’s ability to pump blood. To begin to investigate whether these findings might translate to humans, the study authors collected heart tissue samples from people and found positive correlations between increased UPRmt activation and markers of healthy heart function.”
source: ChromaDex newsletter, April 9, 2019.
Walmart has announced that it will add 300 robots to scan shelves and unload trucks and 1,500 robots to scrub floors. And as the classic Chicago song states: This is “only the beginning; only just the start…
Posted in A.I.
Tagged A.I., robot, walmart
ChromaDex, the makers of the Vitamin B3 derivative NR and sold as Tru Niagen, said they expect a few NR trial results will be published this year. Scientific studies take an average of 10 months to get published but so far the two Elysium studies and the University of Colorado-Boulder study have taken closer to 15 months to publication. Therefore, it is likely that two or three NR trail results will be published this year with more coming in the first half of 2020.
* ChromaDex’s science adviser Charles Brenner (University of Iowa) said a few weeks ago that ChromaDex’s 140 person NR study on adults from 40 to 60 years old taking 100 mg, 300 mg, 1,000 mg or a placebo will be published “soon”, so I assume within a few weeks.
* An NIH study of NR at 1,000 mg on the immune system of adults from 18 to 39 years old was completed last August.
* Elysium’s NR/pterostilbine (Basis) trial on people with acute kidney failure might be out by the end of this year since that study was completed last October.
A pilot study published this week demonstrated that ALS patients taking Elysium Basis showed improvements and a slowing of the disease after taking 1,200 mg of NR (600 mg twice a day) along with some pterostilbine (Elysium Basis) for 4 months. NR is likely to be the main reason for the improvements:
“Differences between EH301 and placebo-treated participants were evaluated based on standard clinical endpoints, including the revised ALS functional rating scale (ALSFRS-R), forced vital capacity (FVC), and the Medical Research Council (MRC) grading scale.
“Results: Compared to placebo, participants treated with EH301 (NR and pterostilbine) demonstrated significant improvements in the ALSFRS-R score, pulmonary function, muscular strength, and in skeletal muscle/fat weight ratio. EH301 [Basis] was shown to significantly slow the progression of ALS relative to placebo, and even showed improvements in several key outcome measures compared with baseline.
I think 2019 is probably too soon but maybe 2020 if human trials of NR (Niagen) for heart failure and dementia are positive. The University of Washington heart failure results should be known in spring or summer and the University of Texas cognitive trial results should be known in 2020.
However, David Sinclair of resveratrol fame and more recently working with NMN wrote a few days ago:
2019 is going to be a watershed year for this field. Just so many things are converging. The science, the business side, the clinical trials reporting out, and the general interest from the public — all of that means that in a year from now, we may find ourselves in one of the most interesting times in human history.
Here is Sinclair’s full statement:
“The molecule that we used is called NMN. We put that in the [mice’s] water supply, and after just a week we saw an increase in endurance. We’re excited about this breakthrough because it shows that we understand why we lose blood flow as we get older, and why we get tired and feel frail. But it also shows that we have a very quick way of reversing that. You could imagine people who are tired, wheelchair-bound, or even bedridden, having energy to get out and exercise again.”
“I think the public doesn’t realize how advanced this technology is and how many investors and companies are also involved. 2019 is going to be a watershed year for this field. Just so many things are converging. The science, the business side, the clinical trials reporting out, and the general interest from the public — all of that means that in a year from now, we may find ourselves in one of the most interesting times in human history.”
I recently compared the percentage of American users of virtual reality to the internet in the 1990s and discovered the trajectories have been about the same:
Internet users in the U.S. (at least once a month)
VR users, U.S. (at least once a month)
2016 10 million (3%)
2017 22 million (7%)
2018 37 million (11%)
2019 49 million (15%) est.
Internet users, worldwide (at least once a month)
VR users, worldwide (at least once a month)
2014 0.2 million
2015 6 million (0.1% of the world)
2016 43 million (0.5% of the world)
2017 90 million (1% of the world)
2018 171 million (2% of the world)
You can see where this is going…
Here are the per capita growth rates since the end of the Cold War (1990):
The People’s Republic of Denmark -2.7%